WO2003011299A3 - Procede et composition pour le traitement de l'hypertension oculaire et des glaucomes - Google Patents

Procede et composition pour le traitement de l'hypertension oculaire et des glaucomes Download PDF

Info

Publication number
WO2003011299A3
WO2003011299A3 PCT/JP2002/007699 JP0207699W WO03011299A3 WO 2003011299 A3 WO2003011299 A3 WO 2003011299A3 JP 0207699 W JP0207699 W JP 0207699W WO 03011299 A3 WO03011299 A3 WO 03011299A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
glaucoma
ocular hypertension
micrograms
keto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/007699
Other languages
English (en)
Other versions
WO2003011299A2 (fr
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Priority to BR0211545-0A priority Critical patent/BR0211545A/pt
Priority to KR10-2004-7001587A priority patent/KR20040023707A/ko
Priority to MXPA04000980A priority patent/MXPA04000980A/es
Priority to US10/485,370 priority patent/US20040254247A1/en
Priority to JP2003516529A priority patent/JP2004538306A/ja
Priority to EP02751774A priority patent/EP1411950A2/fr
Priority to CA002454422A priority patent/CA2454422A1/fr
Publication of WO2003011299A2 publication Critical patent/WO2003011299A2/fr
Publication of WO2003011299A3 publication Critical patent/WO2003011299A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à un procédé servant à traiter l'hypertension oculaire et les glaucomes et qui consiste à administrer en mode topique dans les yeux d'un sujet mammifère nécessitant un tel traitement plus de 5 νg et moins de 50 νg par oeil par administration d'un composé de 15-céto-prostaglandine comportant une structure cyclique à l'extrémité de la chaîne φ. Le traitement faisant l'objet de cette invention ne produit pour ainsi dire pas d'effets secondaires irritants l'oeil ou en produit à un niveau réduit, même à une telle dose élevée.
PCT/JP2002/007699 2001-07-31 2002-07-30 Procede et composition pour le traitement de l'hypertension oculaire et des glaucomes Ceased WO2003011299A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR0211545-0A BR0211545A (pt) 2001-07-31 2002-07-30 Método e composição para tratamento de hipertensão ocular e glaucoma
KR10-2004-7001587A KR20040023707A (ko) 2001-07-31 2002-07-30 안내압항진 및 녹내장의 치료
MXPA04000980A MXPA04000980A (es) 2001-07-31 2002-07-30 Tratamiento de hipertension ocular y glaucoma.
US10/485,370 US20040254247A1 (en) 2001-07-31 2002-07-30 Method and composition for treatnment of ocular hypertension and glaucoma
JP2003516529A JP2004538306A (ja) 2001-07-31 2002-07-30 高眼圧症および緑内障の処置
EP02751774A EP1411950A2 (fr) 2001-07-31 2002-07-30 Procede et composition pour le traitement de l'hypertension oculaire et des glaucomes
CA002454422A CA2454422A1 (fr) 2001-07-31 2002-07-30 Procede et composition pour le traitement de l'hypertension oculaire et des glaucomes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30858901P 2001-07-31 2001-07-31
US60/308,589 2001-07-31

Publications (2)

Publication Number Publication Date
WO2003011299A2 WO2003011299A2 (fr) 2003-02-13
WO2003011299A3 true WO2003011299A3 (fr) 2003-10-30

Family

ID=23194562

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2002/007699 Ceased WO2003011299A2 (fr) 2001-07-31 2002-07-30 Procede et composition pour le traitement de l'hypertension oculaire et des glaucomes
PCT/US2002/024072 Ceased WO2003011178A2 (fr) 2001-07-31 2002-07-31 Procede de traitement pour l'hypertension oculaire et le glaucome

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024072 Ceased WO2003011178A2 (fr) 2001-07-31 2002-07-31 Procede de traitement pour l'hypertension oculaire et le glaucome

Country Status (8)

Country Link
EP (1) EP1411950A2 (fr)
JP (1) JP2004538306A (fr)
KR (1) KR20040023707A (fr)
CN (1) CN1646134A (fr)
BR (1) BR0211545A (fr)
CA (1) CA2454422A1 (fr)
MX (1) MXPA04000980A (fr)
WO (2) WO2003011299A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003215820A1 (en) * 2002-03-28 2003-10-13 Sucampo Ag Method for treating ocular hypertension and glaucoma
US20040225014A1 (en) * 2003-02-14 2004-11-11 Sucampo Ag Method for treating ocular hypertension and glaucoma
EP2069295B1 (fr) * 2006-07-10 2013-12-18 Allergan, Inc. Derives de cyclopentane substitues comme agents therateutiques
ES2549863T3 (es) * 2006-07-11 2015-11-02 Allergan, Inc. Derivados de ciclopentano como agentes antiglaucoma
US20080015219A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Therapeutic compounds
WO2009006370A1 (fr) * 2007-07-03 2009-01-08 Allergan, Inc. Cyclopentanes thérapeutiques substitués pour réduire la pression intraoculaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366279A2 (fr) * 1988-10-01 1990-05-02 R-Tech Ueno Ltd. Agents oculaires hypotenseurs
WO2001068072A2 (fr) * 2000-03-16 2001-09-20 Sucampo Ag Traitement de l'hypertension oculaire et du glaucome
WO2002007731A2 (fr) * 2000-07-20 2002-01-31 Sucampo Ag Composition destinee au traitement de l'hypertension oculaire et du glaucome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366279A2 (fr) * 1988-10-01 1990-05-02 R-Tech Ueno Ltd. Agents oculaires hypotenseurs
WO2001068072A2 (fr) * 2000-03-16 2001-09-20 Sucampo Ag Traitement de l'hypertension oculaire et du glaucome
WO2002007731A2 (fr) * 2000-07-20 2002-01-31 Sucampo Ag Composition destinee au traitement de l'hypertension oculaire et du glaucome
US20020035149A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension and glaucoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STJERNSCHANTZ J ET AL: "MICROVASCULAR EFFECTS OF SELECTIVE PROSTAGLANDIN ANALOGUES IN THE EYE WITH SPECIAL REFERENCE TO LATANOPROST AND GLAUCOMA TREATMENT", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, vol. 19, no. 4, July 2000 (2000-07-01), pages 459 - 496, XP001126960, ISSN: 1350-9462 *

Also Published As

Publication number Publication date
KR20040023707A (ko) 2004-03-18
BR0211545A (pt) 2004-07-13
EP1411950A2 (fr) 2004-04-28
WO2003011299A2 (fr) 2003-02-13
MXPA04000980A (es) 2004-04-20
JP2004538306A (ja) 2004-12-24
CA2454422A1 (fr) 2003-02-13
WO2003011178A2 (fr) 2003-02-13
CN1646134A (zh) 2005-07-27

Similar Documents

Publication Publication Date Title
CA2502437A1 (fr) Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome
WO2002096432A3 (fr) Compositions a base de timolol et de lipide hypotenseur et methodes d'utilisation associees
TWI255714B (en) Method for treating meibomian gland disease
WO2002036162A3 (fr) Compositions et methodes de traitement de la neovascularisation oculaire et des lesions nerveuses
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
CA2440764A1 (fr) Combinaison de brimonidine et de timolol pour utilisation topique ophtalmique
BR9808016A (pt) Composições e métodos para redução da hipertensão ocular
WO2004008990A3 (fr) Correction progressive d'une erreur de refraction de la cornee au moyen d'elements rapportes multiples
CA2198245A1 (fr) Methodes et moyens pour l'administration de medicaments
WO2000018316A3 (fr) Composition ophtalmique agreable, a liberation prolongee, et procede de therapie oculaire
WO2007038687A3 (fr) Administration oculaire d'agents immunosuppresseurs
WO2002009702A8 (fr) Methode de reduction de la pression intraoculaire avec des derives d'indole
WO2001030380A3 (fr) Techniques et compositions destinees au traitement du keratocone au moyen d'inhibiteurs de protease
AU5446299A (en) Medicinal compositions for treating eye diseases
WO1998039293A3 (fr) 13-thia prostaglandines destinees a etre utilisees dans la therapie du glaucome
KR20130052619A (ko) 방부제가 없는 비마토프로스트 및 티몰롤 용액
EP1050308A4 (fr) Mesures prophylactiques ou remedes contre les troubles de la vision
CA2171226A1 (fr) Traitement de troubles au niveau du nerf optique a l'aide de composes de l'acide prostanoique
WO1999043309A3 (fr) Medicaments anticonvulsants et compositions pharmaceutiques de ceux-ci
WO2003011299A3 (fr) Procede et composition pour le traitement de l'hypertension oculaire et des glaucomes
AU609807B2 (en) A composition for the topical treatment of glaucoma or ocular hypertension
WO2003061519A3 (fr) Procedes et compositions preservant la viabilite des cellules photoreceptrices de l'oeil
MXPA03010363A (es) Metodo para tratar hipertension ocular y glaucoma.
CA2414586A1 (fr) Agent de traitement therapeutique des maladies du nerf optique et de maladies semblables
Susanna Jr et al. Additive effect of latanoprost to the combination of timolol and dorzolamide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2454422

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002751774

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003516529

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000980

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047001587

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002355693

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20028190947

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002751774

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10485370

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002751774

Country of ref document: EP